359-364 Effects of controlled-release alpha lipoic acid in lean, nondiabeticpatients with polycystic ovary syndrome

Journal of Diabetes Science and Technology

Volumn 4, Issue 2, 2010, Pages 359-364

  Masharani, Umesh ^a   Gjerde, Christine ^a   Evans, Joseph L ^b   Youngren, Jack F ^a   Goldfine, Ira D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ReceptorBio   (United States)

Author keywords

Cholesterol; Insulin resistance; Oxidative stress; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THIOCTIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; CLASSIFICATION; DELAYED RELEASE FORMULATION; DRUG EFFECT; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINISM; MENSTRUAL CYCLE; METABOLISM; METHODOLOGY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DELAYED-ACTION PREPARATIONS; EXERCISE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERINSULINISM; INSULIN; LIPOPROTEINS, LDL; MENSTRUAL CYCLE; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; THINNESS; THIOCTIC ACID; TRIGLYCERIDES;

EID: 77955490203     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681000400218     Document Type: Article

References (33)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078-82. (Pubitemid 28500937)
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223- 36.
3. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57(2):356-9. (Pubitemid 13032489)
4. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf). 1994;41(4):463-71. (Pubitemid 24301279)
5. Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996;81(8):2854-64. (Pubitemid 26326301)
6. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15(6):1266-74. (Pubitemid 30335948)
7. Ovesen P, Moller J, Ingerslev HJ, Jørgensen JO, Mengel A, Schmitz O, Alberti KG, Moller N. Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1993;77(6):1636-40. (Pubitemid 24000926)
8. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139-46. (Pubitemid 32268804)
9. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod. 2006;21(6):1400-7. (Pubitemid 44445014)
10. Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol. 2008;60(1):63-75. (Pubitemid 351517723)
11. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52(1):1-8. (Pubitemid 36042100)
12. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80(1):123-7.
13. Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med. 2000;28(9):1349-61. (Pubitemid 30621479)
14. Polak G, Kozio?-Montewka M, Tarkowski R, Kotarski J. [Peritoneal fluid and plasma 4-hydroxynonenal and malonyldialdehyde concentrations in infertile women]. Ginekol Pol. 2001;72(12A):1316-20.
15. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34(5):407-13. (Pubitemid 32777851)
16. Evans JL, Heymann CJ, Goldfine ID, Gavin LA. Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. Endocr Pract. 2002;8(1):29-35. (Pubitemid 34126689)
17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
18. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-7.
19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-23. (Pubitemid 9249478)
20. Kulkarni KR, Garber DW, Jones MK, Segrest JP. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res. 1995;36(11):2291-302.
21. Sharma ST, Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers. Best Pract Res Clin Endocrinol Metab. 2006;20(2):245-60. (Pubitemid 43842921)
22. Cibula D. Is insulin resistance an essential component of PCOS?: The influence of confounding factors. Hum Reprod. 2004;19(4):757-9. (Pubitemid 38456035)
23. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454-60. (Pubitemid 40615820)
24. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80(9):2586-93.
25. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82(4):893-902. (Pubitemid 39346435)
26. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607. (Pubitemid 19004941)
27. Wang JF, Schramm DD, Holt RR, Ensunsa JL, Fraga CG, Schmitz HH, Keen CL. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. J Nutr. 2000;130(8S Suppl):2115S-9S.
28. Hutchinson DS, Summers RJ, Bengtsson T. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease. Pharmacol Ther. 2008;119(3):291-310.
29. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab. 2007;33(6):395-402. (Pubitemid 350218220)
30. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-74. (Pubitemid 32995375)
31. Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, Kim MS, Kim SW, Lee KU, Park JY. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun. 2005;332(3):885-91.
32. Huong DT, Ide T. Dietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in rats. Br J Nutr. 2008;100(1):79-87.
33. Park KG, Min AK, Koh EH, Kim HS, Kim MO, Park HS, Kim YD, Yoon TS, Jang BK, Hwang JS, Kim JB, Choi HS, Park JY, Lee IK, Lee KU. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology. 2008;48(5):1477-86.